Depomed Announces Appointment of Santosh J. Vetticaden, M.D., PH.D. as Senior Vice President, Chief Medical and Scientific Of...
October 18 2017 - 8:00AM
Depomed, Inc. (NASDAQ:DEPO) today announced that Santosh J.
Vetticaden, M.D., Ph.D., has joined Depomed as Senior Vice
President, Chief Medical and Scientific Officer.
“Santosh’s deep experience in the area of pain, his proven
ability to collaborate and execute on business development
transactions as well as his strong operational leadership will be
invaluable and immediately applicable to us as we advance our near
and long-term business strategies aimed at improving the patient
experience and building shareholder value,” said Arthur Higgins,
President and Chief Executive Officer of Depomed. “In this role, in
addition to overseeing the Medical and Scientific teams, Santosh
will work alongside our Business Development team to assess
external opportunities as we work to create a more diversified
business. The appointment marks the latest step in strengthening
the organization, one that shares the common purpose of putting the
patient first. We are very pleased to have Santosh join the team
and look forward to his contributions.”
Dr. Vetticaden brings over 25 years of pharmaceutical and
biotechnology industry leadership experience to this role. Most
recently, he held the position of Interim Chief Executive Officer
of Insys Therapeutics Inc., a specialty pharmaceutical company
developing and commercializing products in various therapeutic
areas including the area of pain management. Prior to joining
Insys, Dr. Vetticaden held the role of Chief Medical Officer at
publicly traded biopharmaceutical companies: Mast Therapeutics,
Cubist Pharmaceuticals and Maxygen. Dr. Vetticaden’s professional
career includes holding leadership positions at Johnson &
Johnson and Aventis (now Sanofi). Dr. Vetticaden currently
serves on the board of Heluna Health (formerly Public Health
Foundation Enterprises), a non-profit organization devoted to
population health. Dr. Vetticaden received an M.D. from the
University of Maryland, a Ph.D. from Virginia Commonwealth
University and an M.B.A. from the Sloan School of Management at the
Massachusetts Institute of Technology.
Dr. Vetticaden commented: “I am very pleased to be joining
Depomed now and being able to assist with initiatives aimed at
taking its exciting pain and neurology portfolio to the next level
and assessing opportunities to further diversify its business."
Depomed is a leading specialty pharmaceutical company focused on
enhancing the lives of the patients, families, physicians,
providers and payers we serve through commercializing innovative
products for pain and neurology related disorders. Depomed markets
six medicines with areas of focus that include mild to severe acute
pain, moderate to severe chronic pain, neuropathic pain, migraine
and breakthrough cancer pain. Depomed is headquartered in Newark,
California. To learn more about Depomed, visit www.depomed.com.
"Safe Harbor" Statement under the Private Securities Litigation
Reform Act of 1995. The statements that are not historical facts
contained in this release are forward-looking statements that
involve risks and uncertainties including, but not limited to risks
detailed in the Company's Securities and Exchange Commission
filings, including the Company's most recent Annual Report on Form
10-K and most recent Quarterly Report on Form 10-Q. The inclusion
of forward-looking statements should not be regarded as a
representation that any of the Company's plans or objectives will
be achieved. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof.
The Company undertakes no obligation to publicly release the result
of any revisions to these forward-looking statements that may be
made to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events.
INVESTOR AND MEDIA CONTACT:
Christopher Keenan VP, Investor Relations and Corporate
Communications 510-744-8000 ckeenan@depomed.com
Depomed, Inc. (delisted) (NASDAQ:DEPO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Depomed, Inc. (delisted) (NASDAQ:DEPO)
Historical Stock Chart
From Apr 2023 to Apr 2024